Head-to-head · WeighScore
Fifty 410 vs FMmeds
The verdict
Fifty 410 takes it — 71.3/100 to 63.2/100.
Fifty 410 grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fifty 410 is a direct-to-consumer weight-loss telehealth service offering personalized compounded semaglutide and tirzepatide prescribed by licensed providers and prepared by FDA-registered 503A and 503B…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fifty 410 | FMmeds |
|---|---|---|
| WeighScore | 71.3/100 | 63.2/100 |
| Grade | C | C |
| Scorecard rank | #94 | #257 |
| Semaglutide | $99/mo (all doses, compounded) | $225/mo (all doses, compounded) |
| Tirzepatide | $133/mo (starting dose, compounded) | $265/mo (all doses, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #94 · C
Strengths
- Transparent public pricing from 99 dollars per month for semaglutide
- No membership or subscription; pay only for what you need
- Compounded by FDA-registered 503A and 503B pharmacies
- Fast 24 to 48 hour provider review
- Free one to two day shipping
Where it loses points
- Does not bill insurance directly
- Compounded GLP-1 is not an FDA-approved finished drug
- Specific clinician credentials are not publicly disclosed
- Served-states list is not published on the site
- No branded GLP-1 options
Graded #257 · C
Strengths
- All 50 states plus DC covered, stated in the Terms
- Operating LLC and full Manhattan Beach, CA address disclosed
- Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
- Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
- Flat pricing across all dose strengths — no dose-escalation surcharge
Where it loses points
- Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
- Clinical network not separately named
- LegitScript Certified, but the specific ID isn't shown
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.